MicroRNA-133 controls cardiac hypertrophy

By A. Carè, D. Catalucci, Federica Felicetti, D. Bonci, A. Addario, Paolo Gallo, M. Bang, Patrizia Segnalini, Yusu Gu, N. Dalton and 12 more. Nature Medicine, 2007

1,904 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/3208bc37114479047d540906ecf4e1df54a4117f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

MicroRNA sponges: progress and possibilities. (2010, methodology): “Carè et al. used an adenoviral eGFP sponge to inhibit miR-133 in cardiac myocytes in vivo in a mouse model of cardiac hypertrophy (Carè et al. 2007).”
The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities (2008, background): “Growing evidence indicates that miRNAs control basic cell functions, ranging from proliferation to apoptosi”
Altered microRNA expression in human heart disease. (2007, background): “miR-1 was recently reported to be downregulated in four different murine models of cardiac hypertrophy or failure (4, 15), consistent with our finding of miR-1 downregulation in AS and DCM.”
Mechanistic Pathways of Sex Differences in Cardiovascular Disease. (2017, background): “The expression of several 100s different miRNAs has been described in the mouse heart, many of which are regulated during the development of LV hypertrophy (53, 70, 346, 378, 390, 401).”
Non-coding RNAs in disease: from mechanisms to therapeutics (2023, positive): “…particularly human cancers, such as by functioning as oncogenes and/or tumour suppressors 8 . miRNAs have also been found to be differentially expressed in a range of other human pathologies, including cardiovascular diseases (CVDs) 9,10 , neurological diseases 6,7 and infectious diseases 11 .”
MicroRNA function in cancer: oncogene or a tumor suppressor? (2009, background): “In the heart, miR-1 and miR-133, which belong to the same transcriptional unit, have a critical function in determining cardiomyocyte hypertrophy [22].”
Transcriptional Regulation and its Misregulation in Disease (2013, positive): “…disease, including arrhythmia, fibrosis, hypertrophy due to high pressure and misregulation of cardiac energy metabolism (Callis et al., 2009; Care et al., 2007; Grueter et al., 2012; Luo et al., 2008; Thum et al., 2008; van Rooij et al., 2007; van Rooij et al., 2008; Yang et al., 2007).”